Business Context and Reporting Period
Revolution Medicines, Inc. (RVMD) filed a Current Report on Form 8-K on April 14, 2026, regarding a material definitive agreement and the creation of a direct financial obligation. The company, incorporated in Delaware and headquartered in Redwood City, California, is an emerging growth company.
Key Financial Metrics and Transaction Details
The filing details the issuance of $500,000,000 aggregate principal amount of 0.50% Convertible Senior Notes due 2033. Key terms include:
- Principal Amount: $500,000,000
- Interest Rate: 0.50% per annum, payable semi-annually in arrears beginning November 1, 2026.
- Maturity Date: May 1, 2033.
- Conversion Rate: Initial rate of 5.0302 shares of common stock per $1,000 principal amount (approx. $198.80 conversion price).
- Settlement: Cash, shares, or a combination at the Company's election.
- Underwriters: J.P. Morgan Securities LLC, TD Securities (USA) LLC, and Guggenheim Securities, LLC.
The filing text does not provide specific values for revenue, profit, cash flow, operating margins, or existing debt levels prior to this transaction.
Material Changes Versus Prior Period
This filing represents a significant change in the company's capital structure through the addition of $500 million in senior, unsecured indebtedness. The Notes are equal in right of payment to existing senior unsecured debt but are structurally subordinated to subsidiary liabilities. No comparative financial data for prior periods is included in this specific 8-K filing.
Guidance, Outlook, and Risks
Redemption and Conversion: The Company may redeem the Notes on or after May 6, 2030, if the stock price exceeds 130% of the conversion price for a specified period. Holders may convert notes upon certain events before February 1, 2033, and at any time thereafter until maturity.
Fundamental Change Repurchase: If a "Fundamental Change" occurs (e.g., business combination or delisting), noteholders may require the Company to repurchase the Notes at 100% of principal plus accrued interest.
Events of Default: Includes payment defaults, failure to convert, bankruptcy, and defaults on other indebtedness of at least $100 million. Bankruptcy events trigger immediate acceleration of all outstanding Notes.
Management Commentary: The filing contains no forward-looking guidance or management commentary regarding operational outlook, only the terms of the debt instrument.
Investor Verification Checklist
- Verify the impact of the $500 million debt issuance on the company's total leverage and liquidity position.
- Confirm the current market price of RVMD common stock relative to the $198.80 conversion price to assess immediate conversion risk.
- Review the full Indenture (Exhibits 4.1 and 4.2) for specific covenants restricting future operations or additional debt.
- Assess the company's cash burn rate to ensure sufficient liquidity for semi-annual interest payments starting November 2026.
- Monitor for any "Fundamental Change" events that could trigger a mandatory repurchase obligation.